Advanced search    

Search: authors:"Guntram Schernthaner"

33 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Individualisierung der antihypertensiven Therapie bei Patienten mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2019)

visit: www.escardio.org. OUP and ESC are not responsible or in any way liable for the accuracy of the translation. Guntram Schernthaner is solely responsible for the translation in this publication. This ... responsible or in any way liable for the accuracy of the translation. Guntram Schernthaner is solely responsible for the translation in this publication. This figure is not included under the Creative Commons

Diabetische Nierenerkrankung (Update 2019)

ZusammenfassungRezente epidemiologische Untersuchungen zeigen, dass etwa 2–3 % aller Österreicher Diabetes mit Nierenbeteiligung aufweisen. Diese betrifft somit in Österreich etwa 250.000 Menschen. Das Risiko des Auftretens und Fortschreitens der Erkrankung kann durch Lebensstilinterventionen und Optimierung der Einstellung des Blutdrucks, Blutzuckers und spezielle...

Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies

1, Rudolfstiftung Hospital , Juchgasse 25, 1030 Vienna , Austria 1 Guntram Schernthaner 2 Abbreviations CKD Chronic kidney disease CVD Cardiovascular disease DPP-4 Dipeptidyl peptidase-4 ESRD End

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)

) Guntram Schernthaner,1 Kamlesh Khunti,2 Chaim Lotan,3 Michel Burnier,4 Heinz Drexel,5 Martin Prázný61Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria; 2Diabetes Research Centre, Leicester

Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2019)

, Novo Nordisk, sanofi-aventis, Servier, Ypsomed. Guntram Schernthaner hat Lectures gehalten für: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Mundipharma, Novo Nordisk, Servier, Takeda. Sourij Harald hat

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

Expert Group (CEEDEG) Guntram Schernthaner 0 Roger Lehmann 2 Martin Prázný 1 Leszek Czupryniak 7 Kristine Ducena 6 Peter Fasching 5 Andrej Janež 4 Avraham Karasik 9 Peter Kempler 8 Emil Martinka 3 Marina

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

Objective The risk of cardiovascular morbidity and mortality is significantly increased in patients with diabetes; thus, it is important to determine whether glucose-lowering therapy affects this risk over time. Changes in cardiovascular risk markers were examined in patients with type 2 diabetes treated with exenatide twice daily (a glucagon-like peptide-1 receptor agonist) or...

Kidney disease in diabetology: lessons from 2010

Guntram Schernthaner 0 0 Department of Medicine I, Rudolfstiftung Hospital , A-1030 Juchgasse 25, Vienna, Austria 38. Bellomo R, Ronco C, Kellum JA et al. Acute Dialysis Quality Initiative

Diabetische Nierenerkrankung – Update 2016

2 Harald Sourij · Roland Edlinger · Friedrich Prischl · Martin Auinger · Alexandra Kautzky-Willer · Marcus D. Säemann · Rudolf Prager · Martin Clodi · Guntram Schernthaner · Gert Mayer · Rainer

Kidney disease in diabetology: lessons from 2008

Guntram Schernthaner 0 1 0 the Department of Medicine I, Rudolfstiftung Hospital-Vienna , Juchgasse 25, A - 1030 Vienna, Austria . Tel: 1 Department of Medicine I, Rudolfstiftung Hospital , Vienna

Hypoglycemia and Cardiovascular Risks

BRIAN M. FRIER 0 GUNTRAM SCHERNTHANER 0 SIMON R. HELLER 0 0 Frier, Schernthaner, and Heller - A common side effect of insulin therlthough hypoglycemia is the most apy in diabetes and its morbidity

Kidney disease in diabetology: lessons from 2007

Guntram Schernthaner 0 1 0 Rudolfstiftung Hospital , A-1030, Juchgasse 25, Vienna, Austria . Tel: 1 Department of Medicine I, Rudolfstiftung Hospital , Vienna, Austria Introduction Diabetic

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial

GUNTRAM SCHERNTHANER JORGE L. GROSS JULIO ROSENSTOCK MICHAEL GUARISCO MIN FU MS JACQUELINE YEE MS MASATO KAWAGUCHI WILLIAM CANOVATCHEL GARY MEININGER OBJECTIVEdTo evaluate the efficacy and safety of

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

PASCALE FOUQUERAY VALDIS PIRAGS SILVIO E. INZUCCHI CLIFFORD J. BAILEY PHD GUNTRAM SCHERNTHANER MICHAELA DIAMANT HAROLD E. LEBOVITZ OBJECTIVEdA 12-week study assessed the efficacy and safety of a new

Kidney disease in diabetology

Guntram Schernthaner 0 1 0 MD, Professor of Medicine Liaison Editor (Diabetology), NDT, Head of the Department of Medicine I, Rudolfstiftung Hospital 1 Department of Medicine I, Rudolfstiftung